127 related articles for article (PubMed ID: 10832591)
1. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.
Gion M; Boracchi P; Dittadi R; Biganzoli E; Peloso L; Gatti C; Paccagnella A; Rosabian A; Vinante O; Meo S
Breast Cancer Res Treat; 2000 Feb; 59(3):211-21. PubMed ID: 10832591
[TBL] [Abstract][Full Text] [Related]
2. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
4. Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Brandes A; Vinante O; Bruscagnin G
Eur J Cancer; 1992; 29A(1):66-9. PubMed ID: 1445748
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer.
Hupperets PS; Volovics L; Schouten LJ; Jager JJ; Schouten HC; Hillen HF; Blijham GH
Am J Clin Oncol; 1997 Dec; 20(6):546-51. PubMed ID: 9391537
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
9. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
[TBL] [Abstract][Full Text] [Related]
11. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
[TBL] [Abstract][Full Text] [Related]
12. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
13. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
14. Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance.
Corte MD; Vérez P; Rodríguez JC; Roibás A; Domínguez ML; Lamelas ML; Vázquez J; García Muñiz JL; Allende MT; González LO; Fueyo A; Vizoso F
Breast Cancer Res Treat; 2005 Mar; 90(1):33-40. PubMed ID: 15770524
[TBL] [Abstract][Full Text] [Related]
15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
16. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up.
Mauri FA; Maisonneuve P; Caffo O; Veronese S; Aldovini D; Ferrero S; Cozzaglio F; Dalla Palma P; Galligioni E; Barbareschi M
Int J Oncol; 1999 Dec; 15(6):1137-47. PubMed ID: 10568820
[TBL] [Abstract][Full Text] [Related]
18. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
